COX-2 inhibitors in cancer treatment and prevention, a recent development - PubMed (original) (raw)

Review

COX-2 inhibitors in cancer treatment and prevention, a recent development

Xiao-Chun Xu. Anticancer Drugs. 2002 Feb.

Abstract

Epidemiological and experimental studies have demonstrated the effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the prevention of human cancers. NSAIDs block endogenous prostaglandin synthesis through inhibition of cyclooxygenase (COX) enzymatic activity. COX-2, a key isoenzyme in conversion of arachidonic acid to prostaglandins, is inducible by various agents such as growth factors and tumor promoters, and is frequently overexpressed in various tumors. The contribution of COX-2 to carcinogenesis and the malignant phenotype of tumor cells has been thought to be related to its abilities to (i) increase production of prostaglandins, (ii) convert procarcinogens to carcinogens, (iii) inhibit apoptosis, (iv) promote angiogenesis, (v) modulate inflammation and immune function, and (vi) increase tumor cell invasiveness, although some studies indicated that NSAIDs have COX-2-independent effects. A number of clinical trials using COX-2 inhibitors are in progress, and the results from these studies will increase our understanding of COX-2 inhibition in both cancer treatment and prevention. The combination of COX-2 inhibitors with radiation or other anti-cancer or cancer prevention drugs may reduce their side effects in future cancer prevention and treatment. Recent progress in the treatment and prevention of cancers of the colon, esophagus, lung, bladder, breast and prostate with NSAIDs, especially COX-2 inhibitors, is also discussed.

PubMed Disclaimer

Cited by

COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma.
Behling F, Suhm E, Ries V, Gonçalves VM, Tabatabai G, Tatagiba M, Schittenhelm J. Behling F, et al. Neurol Res Pract. 2021 Mar 1;3(1):11. doi: 10.1186/s42466-021-00111-6. Neurol Res Pract. 2021. PMID: 33641674 Free PMC article.
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.
Wang Y, Cui L, Georgiev P, Singh L, Zheng Y, Yu Y, Grein J, Zhang C, Muise ES, Sloman DL, Ferguson H, Yu H, Pierre CS, Dakle PJ, Pucci V, Baker J, Loboda A, Linn D, Brynczka C, Wilson D, Haines BB, Long B, Wnek R, Sadekova S, Rosenzweig M, Haidle A, Han Y, Ranganath SH. Wang Y, et al. Oncoimmunology. 2021 Mar 18;10(1):1896643. doi: 10.1080/2162402X.2021.1896643. Oncoimmunology. 2021. PMID: 33796403 Free PMC article.
COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers.
Rodrigues P, Bangali H, Hammoud A, Mustafa YF, Al-Hetty HRAK, Alkhafaji AT, Deorari MM, Al-Taee MM, Zabibah RS, Alsalamy A. Rodrigues P, et al. Med Oncol. 2024 Jan 2;41(1):41. doi: 10.1007/s12032-023-02256-7. Med Oncol. 2024. PMID: 38165473 Review.
Inflammation in Urological Malignancies: The Silent Killer.
Catalano M, Roviello G, Santi R, Villari D, Spatafora P, Galli IC, Sessa F, Conte FL, Mini E, Cai T, Nesi G. Catalano M, et al. Int J Mol Sci. 2023 Jan 3;24(1):866. doi: 10.3390/ijms24010866. Int J Mol Sci. 2023. PMID: 36614308 Free PMC article. Review.
The tumor microenvironment and its contribution to tumor evolution toward metastasis.
Lorusso G, Rüegg C. Lorusso G, et al. Histochem Cell Biol. 2008 Dec;130(6):1091-103. doi: 10.1007/s00418-008-0530-8. Epub 2008 Nov 6. Histochem Cell Biol. 2008. PMID: 18987874 Review.

COX-2 inhibitors in cancer treatment and prevention, a recent development - PubMed (original) (raw)